Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen entitled to permanent Roche injunction

Amgen entitled to permanent Roche injunction

3rd October 2008

Amgen revealed yesterday that it is entitled to a permanent injunction that bans Roche from retailing Mircera, its pegylated-erythropoietin (peg-EPO), in the US.

Previously, a court ruling confirmed a preliminary injunction, but it will be made permanent once Amgen’s appeal against the former is resolved.

The district court in Boston said that without a permanent injunction, there would be a risk of undermining incentives for the production and future development of such medical advances.

“Amgen is pleased with today’s ruling, which recognizes that Amgen is entitled to a permanent injunction against Roche and reaffirms the infringement and validity of our patents,” said company senior vice-president and general counsel David Scott.

He added the company remains committed to “innovative research and to delivering medicines that treat grievous illness and meet unmet medical needs”.

Separately, a court decision relating to Amgen’s suit against TKT and Aventis resulted in another permanent injunction that prohibits the latter from the SU sale of its gene-activated EPO.

Last month saw Amgen participate in the New York City UBS Global Life Sciences Conference and the Merrill Lynch Pharmaceutical, Biotech & Medical Devices Conference in London.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.